Status:
UNKNOWN
Development and Validation of "Ready-to-Use" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19
Lead Sponsor:
Mansoura University
Conditions:
Covid19
Hydroxychloroquine Adverse Reaction
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
In this project, we aimed at developing new "Ready-to-Use" inhalable forms of HCQ that can be used directly through nebulization or using dry powder inhalers (DPIs). These inhaled forms would allow a ...
Eligibility Criteria
Inclusion
- Age ≥ 18 year
- Laboratory (RT-PCR) positive of SARS-COV-2 (Moderate cases)
- Chest CT with pneumonia.
- SaO2/SPO2 ratio \> 93% or PaO2/FIO2 ratio \> 300 mmHg under the condition in the hospital room.
- Welling to participate and able to give fully informed consent
Exclusion
- Severe and critical illness.
- Retinopathy and other retinal diseases.
- Arrhythmias.
- QT ≥ 400 msec
- Receiving cardiac drugs
- Severe liver disease.
- Pregnancy or lactation.
- Previous treatment of COVID-19.
Key Trial Info
Start Date :
July 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 15 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04477083
Start Date
July 15 2020
End Date
August 15 2020
Last Update
July 20 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mansoura University Hospital
Al Mansurah, Outside U.S./Canada, Egypt, 35516